Anal canal - Medium Biopsy 1-3 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Medium-sized biopsy from anal canal.

₹370₹529

30% OFF

Anal Canal - Medium Biopsy (1-3 cm)

Why is it done?
- Diagnosis of suspicious lesions: To obtain tissue samples from abnormal growths, ulcers, or discolored areas in the anal canal for histopathological examination
- Detection of malignancy: To identify or rule out anal canal cancer, including squamous cell carcinoma, adenocarcinoma, and other neoplastic conditions
- Assessment of inflammatory conditions: To diagnose chronic inflammatory diseases, infectious processes (HPV, herpes), or other pathological conditions affecting the anal canal
- Evaluation of persistent symptoms: To investigate persistent pain, bleeding, drainage, or other chronic anal symptoms of unknown etiology
- HPV-related lesions: To assess and confirm anal intraepithelial neoplasia (AIN) or condylomatous lesions associated with human papillomavirus infection
- Timing: Performed during anoscopy or flexible sigmoidoscopy when visual examination reveals abnormalities or when clinically indicated by patient presentation
Normal Range
- Normal/Negative result: Benign tissue with normal anal canal epithelium (stratified squamous epithelium transitioning to columnar epithelium), absence of dysplasia, malignancy, or significant inflammation
- Normal histological findings: Regular mucosal architecture, normal cellular maturation, intact epithelial-stromal interface, and absence of atypical cells
- Units of measurement: Tissue specimen (1-3 cm sample size), evaluated qualitatively by pathological examination
- Interpretation of normal: Indicates absence of malignancy, dysplasia, or significant pathological changes; provides reassurance regarding investigated lesion
Interpretation
- Negative/Benign findings: Normal tissue architecture, chronic inflammation only, or inflammatory bowel disease changes without dysplasia; indicates no malignancy present
- Anal Intraepithelial Neoplasia (AIN) Grade 1: Mild dysplasia with abnormal nuclei in lower third of epithelium; associated with HPV; requires monitoring and possible treatment
- Anal Intraepithelial Neoplasia (AIN) Grade 2: Moderate dysplasia extending to middle third of epithelium; increased risk of progression to malignancy; requires active management and close follow-up
- Anal Intraepithelial Neoplasia (AIN) Grade 3: Severe dysplasia involving full thickness of epithelium; considered carcinoma in situ; high risk for progression to invasive cancer; requires aggressive treatment
- Invasive Squamous Cell Carcinoma: Malignant cells penetrating basement membrane; may be keratinizing or non-keratinizing; requires staging and multimodal cancer treatment
- Adenocarcinoma: Malignant glandular tumor, often arising from remnants of embryological structures; requires surgical and/or chemotherapy intervention
- Infectious processes: HPV (with koilocytic changes), herpes simplex, or other pathogens identified; guides antimicrobial or antiviral therapy
- Inflammatory/benign conditions: Crohn's disease, ulcerative colitis, hemorrhoids, anal fissures, or infection findings; guides conservative or specific medical management
- Factors affecting interpretation: Immunocompromised status (especially HIV/AIDS), smoking history, HPV exposure, sexual practices, age, and prior anal procedures or treatments
Associated Organs
- Primary organ system: Digestive system (gastrointestinal tract); specifically the anal canal and rectum
- Diseases diagnosed or monitored: Anal canal squamous cell carcinoma, adenocarcinoma, anal intraepithelial neoplasia (AIN), HPV-related lesions and condylomas, inflammatory bowel disease with anal involvement, infectious proctitis, anal melanoma (rare), and lymphoma involving the anal canal
- Risk factors and associations: HIV/AIDS status, smoking, HPV infection, receptive anal intercourse, immunosuppression, history of cervical/vulvar/penile cancer, and chronic inflammatory bowel disease
- Potential complications from abnormal results: Progression from dysplasia to invasive cancer if untreated, dissemination of malignancy to regional lymph nodes and distant sites, fecal incontinence or constipation if extensive treatment required, sexual dysfunction, and psychosocial impact of cancer diagnosis
- Related organ involvement: Rectum, sigmoid colon, perirectal lymph nodes, and in females, cervix and vulva (which often have concurrent HPV-related lesions)
Follow-up Tests
- If benign/normal findings: Clinical follow-up based on symptoms; cytology (anal Pap smear) if warranted; consideration of routine screening if high-risk patient
- If AIN Grade 1 diagnosed: Repeat anoscopy and biopsy in 12 months; consider topical or ablative therapy; HPV testing (if not already performed); repeat cytology screening
- If AIN Grade 2-3 diagnosed: Definitive ablative or excisional therapy; repeat anoscopy with biopsy in 6 months; close surveillance every 3-6 months for 2 years; consideration of immunotherapy in select cases
- If invasive cancer diagnosed: Urgent staging studies (CT abdomen/pelvis, MRI for local staging, chest imaging); HIV testing (if status unknown); baseline tumor markers; oncology consultation; consider chemoradiation therapy (Nigro protocol standard); follow-up imaging and clinical assessment post-treatment
- If infectious process identified: HPV serology/testing; herpes simplex PCR if indicated; sexual partner evaluation; appropriately targeted antimicrobial or antiviral therapy; follow-up examination after treatment completion
- Related complementary tests: Anal cytology (Pap smear), HPV genotyping, digital rectal examination, flexible sigmoidoscopy/colonoscopy, immunohistochemistry studies (p16, p53, Ki-67), and CD4 count if HIV-positive
- Monitoring frequency: Depends on diagnosis: benign lesions (annually if high-risk); AIN Grade 1 (every 12 months); AIN Grade 2-3 (every 3-6 months for 2 years); cancer patients (every 3 months first 2 years, then every 6 months for 5 years or per oncology protocol)
Fasting Required?
- Fasting requirement: No fasting required for the biopsy itself; however, bowel preparation may be recommended
- Bowel preparation: Patients should typically have a bowel movement or receive an enema 1-2 hours before the procedure; alternatively, a bisacodyl suppository (Dulcolax) 15-30 minutes prior to procedure; clear the anal canal and distal rectum of stool
- Medication management: Continue all regular medications; no need to hold anticoagulants unless specified by provider; consider pain management or anxiolytics if patient anxiety is significant; discuss antibiotic prophylaxis with physician if patient has cardiac conditions or immunocompromise
- Pre-procedure instructions: Light breakfast or lunch acceptable on day of procedure; adequate hydration; void bladder before procedure; wear comfortable, easily removable clothing; arrange transportation if conscious sedation or anesthesia planned; notify provider of allergies, especially to lidocaine or other anesthetics
- Special considerations: Inform provider of active anal pain, hemorrhoids, fissures, or other anal pathology; discuss bleeding risk and potential need for hemostasis if on anticoagulants; women should not schedule during menses if possible; post-procedure rest recommended for 24 hours; avoid strenuous activity for 2-3 days

How our test process works!